Both mouse and human studies suggest that tumor cells evade NKG2D recognition either by downregulating NKG2D ligands expression (14, 58) or by secreting massively circulating NKG2D ligands resulting in a downregulation of NKG2D expression on cytotoxic cells (59–61). This evidence concerns the gene KLRK1 and neoplasm.